Holen Sie sich die Stockscreener-App
24.45
1.83%
0.44
Handel nachbörslich:
15.26
-9.19
-37.59%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$24.01
Offen:
$24.27
24-Stunden-Volumen:
11.00M
Relative Volume:
1.53
Marktkapitalisierung:
$2.39B
Einnahmen:
$2.48B
Nettoeinkommen (Verlust:
$-57.96M
KGV:
-32.23
EPS:
-0.7585
Netto-Cashflow:
$-453.97M
1W Leistung:
+4.04%
1M Leistung:
+7.99%
6M Leistung:
-61.50%
1J Leistung:
-80.17%
1-Tages-Spanne:
$22.67
$24.55
1-Wochen-Bereich:
$22.67
$24.55
52-Wochen-Spanne:
$10.41
$138.81
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Firmenname
Sarepta Therapeutics Inc
Sektor
Branche
Telefon
617-274-4000
Adresse
215 FIRST STREET, CAMBRIDGE, MA
Vergleichen Sie SRPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
24.45 | 2.51B | 2.48B | -57.96M | -453.97M | -0.7585 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-22 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-07-29 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-07-29 | Bestätigt | H.C. Wainwright | Sell |
| 2025-07-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-07-29 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-07-28 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-07-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-07-24 | Eingeleitet | Citigroup | Sell |
| 2025-07-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-07-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-07-21 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-07-21 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | Herabstufung | Mizuho | Outperform → Neutral |
| 2025-07-21 | Herabstufung | Needham | Hold → Underperform |
| 2025-07-21 | Herabstufung | UBS | Buy → Neutral |
| 2025-07-18 | Herabstufung | Needham | Buy → Hold |
| 2025-06-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-06-17 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-06-16 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-06-16 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | Herabstufung | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2025-04-02 | Hochstufung | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-11-27 | Bestätigt | Needham | Buy |
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Sell |
| 2024-11-07 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-07-29 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-12-13 | Fortgesetzt | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-21 | Eingeleitet | Wedbush | Outperform |
| 2023-10-31 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-04 | Eingeleitet | Citigroup | Buy |
| 2023-03-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Bestätigt | BTIG Research | Buy |
| 2022-12-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Bestätigt | Needham | Buy |
| 2021-12-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-08-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-01-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-11 | Herabstufung | UBS | Buy → Neutral |
| 2021-01-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Eingeleitet | Mizuho | Buy |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-08-21 | Bestätigt | Needham | Buy |
| 2019-07-09 | Bestätigt | Morgan Stanley | Overweight |
| 2019-07-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-10-12 | Eingeleitet | Bernstein | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Bestätigt | RBC Capital Mkts | Outperform |
| 2018-09-14 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-09-06 | Eingeleitet | Credit Suisse | Outperform |
| 2018-08-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Bestätigt | Robert W. Baird | Outperform |
| 2018-06-20 | Bestätigt | Needham | Buy |
| 2018-06-19 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
Capricor Therapeutics Stock Becomes Talk Of Retail Town On DMD Study; Retail Sees New Hope After Sarepta Setback - Stocktwits
Sarepta Therapeutics (SRPT) to Join S&P SmallCap 600 - GuruFocus
Why Sarepta Therapeutics Shares Tumbled Today - TipRanks
Why Is Sarepta Stock (SRPT) Crashing in Pre-Market Today? - TipRanks
Earnings Snapshot: Sarepta Q3 beat; ESSENCE study did not meet statistical significance on primary endpoint - MSN
Sarepta Therapeutics Stock Crashes After-Hours On DMD Trial Failure, Q3 Print — Retail Still Sees Long-Term Comeback - Stocktwits
Sarepta Therapeutics Reports Q3 2025 Financial Results - TipRanks
Transcript : Sarepta Therapeutics, Inc., Q3 2025 Earnings Call, Nov 03, 2025 - MarketScreener
Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE - BioSpace
Sarepta Therapeutics (SRPT): Assessing Valuation After Q3 Earnings Reveal Swing to Net Loss - simplywall.st
Sarepta's shares sink after antisense DMD therapies fail confirmatory trial - FirstWord Pharma
Sarepta Therapeutics: Q3 Earnings Snapshot - CTPost
Sarepta Therapeutics Outpaces Forecasts On Gene Therapy Strength - Finimize
Earnings call transcript: Sarepta Therapeutics beats Q3 2025 EPS forecast - Investing.com
Sarepta's shares plunge after trial for muscle-wasting disease drugs miss key goal - Reuters
Sarepta Therapeutics Stock: Strong Q3 and ESSENCE Study Results Propel Future Growth Plans - parameter.io
Sarepta’s stock plummets as disappointing trial data raise questions on DMD drug’s success - MarketWatch
Sarepta Therapeutics (SRPT) Shares Plunge 20% After Trial Setbac - GuruFocus
Sarepta Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Sarepta Says Older Muscle Disease Drugs Failed Confirmatory Trial - Bloomberg.com
Sarepta Therapeutics (SRPT) Reports Q3 Loss, Beats Revenue Estimates - Yahoo! Finance Canada
Sarepta Therapeutics (SRPT) Beats Q3 Earnings Expectations Despi - GuruFocus
Sarepta plunges after late-stage Duchenne trial failure - MSN
After-hours movers: Palantir, Hims & Hers Health, Sarepta Therapeutics, Sanmina - Investing.com
Sarepta plunges after late-stage Duchenne trial failure (SRPT:NASDAQ) - Seeking Alpha
Sarepta Therapeutics Stock Is Tumbling After The Close: Here's Why - Benzinga
Sarepta reports mixed results from confirmatory trial for rare disease therapies - Investing.com
Sarepta Therapeutics tumbles after ESSENCE trial misses primary endpoint By Investing.com - Investing.com Nigeria
Sarepta Therapeutics tumbles after ESSENCE trial misses primary endpoint - Investing.com India
Sarepta Therapeutics Q3 2025 Earnings: Revenue Surpasses Estimat - GuruFocus
Sarepta shares dive as gene therapy misses late-stage main goal - TradingView
Sarepta Therapeutics Q3 revenue beats estimates on strong show from gene therapy ELEVIDYS - MarketScreener
Sarepta's Duchenne gene therapy misses main goal in late-stage study; shares fall - Yahoo Finance
Sarepta stock plunges after ESSENCE trial misses primary endpoint By Investing.com - Investing.com Canada
Sarepta's Duchenne gene therapy misses main goal in study - MarketScreener
Sarepta Crashes After Two Muscular Dystrophy Drugs Fail Confirmatory Tests - Investor's Business Daily
Earnings Flash (SRPT) Sarepta Therapeutics, Inc. Posts Q3 Adjusted Loss $0.13 per Share - MarketScreener
Sarepta completes confirmatory study for duchenne therapies, study misses primary endpoint - StreetInsider
Price-Driven Insight from (SRPT) for Rule-Based Strategy - news.stocktradersdaily.com
Is Sarepta Therapeutics Inc. stock supported by strong cash flows2025 Short Interest & Community Consensus Picks - newser.com
SRPT Crosses Above Average Analyst Target - Nasdaq
Forecasting Sarepta Therapeutics Inc. price range with options dataIPO Watch & Real-Time Chart Pattern Alerts - newser.com
What market sentiment indicators show for Sarepta Therapeutics Inc. (AB3A) stockQuarterly Performance Summary & Consistent Return Investment Signals - newser.com
Can Sarepta Therapeutics Inc. (AB3A) stock attract analyst upgrades2025 Support & Resistance & Weekly Momentum Picks - newser.com
Smart tools for monitoring Sarepta Therapeutics Inc.’s price action2025 Volume Leaders & Long-Term Capital Growth Ideas - newser.com
Will breakout in Sarepta Therapeutics Inc. lead to full recoveryGold Moves & Accurate Intraday Trade Tips - newser.com
Is Sarepta Therapeutics Inc. stock ready for a breakoutQuarterly Portfolio Review & Daily Profit Focused Screening - newser.com
Combining machine learning predictions for Sarepta Therapeutics Inc.July 2025 Trade Ideas & Stock Portfolio Risk Management - newser.com
State of New Jersey Common Pension Fund D Grows Stock Holdings in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
How Sarepta Therapeutics Inc. stock benefits from global expansionMarket Risk Summary & Weekly High Potential Stock Alerts - newser.com
Relative strength of Sarepta Therapeutics Inc. in sector analysisQuarterly Profit Review & Community Verified Watchlist Alerts - newser.com
Finanzdaten der Sarepta Therapeutics Inc-Aktie (SRPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):